Erlotinib Analogs (CoNCERT)

N/A

Report date: 2026/05/13 20:02:10
NME

Base Information

Drug NameErlotinib Analogs (CoNCERT)
Drug Alias NameHER1 inhibitor (CoNCERT)Epidermal Growth Factor Antagonist (CoNCERT)EGFR Antagonist (CoNCERT)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsEGFR 19del inhibitorsEGFR L858R inhibitors
TargetsEpidermal growth factor receptor erbB1EGFR 19delEGFR L858R
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesConcert Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesConcert Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A